Company / CIK 0001693011
Inozyme Pharma, Inc.
- Ticker
- INZY
- Insiders on file
- 1
- Federal contracts on record
- none matched
- Lobbying filings on record
- 1
- SEC filings
- EDGAR ↗
- Latest trade on record
- July 28, 2020
Inozyme Pharma, Inc. (INZY) has 1 insider on file who disclosed 0 transactions in the last 12 months (0 open-market buys, 0 sales, about $0 at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Sanofi | Insider | 3 | 1 | 0 | August 12, 2026 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi | INZY | Exchange C | July 28, 2020 | July 29, 2020 | 1d | 3,279,720 | — | — | indirectderivative | Form 4 ↗ | |
| Sanofi | INZY | Buy P | July 28, 2020 | July 29, 2020 | 1d | 81,250 | $16 | $1.3M | indirect | Form 4 ↗ | |
| Sanofi | INZY | Exchange C | July 28, 2020 | July 29, 2020 | 1d | 438,875 | — | — | indirect | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Inozyme Pharma, Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
| Period | Registrant | Primary issue | Amount | Source |
|---|---|---|---|---|
| 2025 Q3 | THE KPM GROUP DC LLC | — | — | LDA ↗ |
Related companies
Companies whose stock was traded by the same people who traded INZY, by number of filers in common. It shows overlap in public filings and nothing else.
- REGENERON PHARMACEUTICALS, INC. REGN 1 filer in common
- Attovia Therapeutics, Inc. ATTO 1 filer in common
- Latigo Biotherapeutics, Inc. LTGO 1 filer in common
- Fulcrum Therapeutics, Inc. FULC 1 filer in common
- Icosavax, Inc. ICVX 1 filer in common
- Translate Bio, Inc. TBIO 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Lobbying disclosure reports Reports are due about 20 days after each quarter ends.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 3 | July 29, 2020 | July 29, 2020 | Form 4 list on EDGAR |
| Lobbying disclosure filings | 1 filing | — | — | — | LDA.gov search |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.